‘Astonishing’ AI Predicts Over 1,000 Diseases Decades in Advance
Remember the last time you visited the doctor? They likely asked you about your medical history. For many…
US Birth Control, Indian Drugs at Risk From Trump’s 250% Tariff Threat
US President Donald Trump’s threat of imposing tariffs as high as 250%Bloomberg Terminal on pharmaceutical imports is putting…
How Indigenous-led health education in remote communities can make reconciliation real
If Canada is serious about reconciliation, it must change how it trains health professionals. Right now, too few…
Hospitals Deploying Robot Programmed to Act Like Child to Comfort Pediatric Patients
A new face is lighting up hospitals and nursing homes across the country. It’s an animated, cartoonish persona…
GPs to re-check some patients for deadly ‘misses’
Philippa RoxbyHealth reporter Andrea Brady Jessica Brady contacted her GP practice more than 20 times feeling unwell GPs…
Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy — TradingView News
The financial market is a machine powered by shifting opinions, and when the Federal Reserve announced its latest…
1 Reason Medtronic (MDT) Is One of the Best Healthcare Stocks You Can Buy Today
Medtronic is one of the largest medical device makers in the world, and it is focused on getting…
If A.I. Can Diagnose Patients, What Are Doctors For?
It seems inevitable that the future of medicine will involve A.I., and medical schools are already encouraging students…
Rural health clinics are starting to close, raising the political risks of Trump’s ‘One Big Beautiful Bill’
Facebook Tweet Email Link Exactly two months after President Donald Trump signed his policy megabill in a July…
PE fund KKR closes third buy in Kerala, at Meitra Hospital
Global private equity firm KKR, which had notched a fivefold return in its exit from Max Healthcare, is…
How Good People Lose Their Way In Healthcare
Former Mylan CEO Heather Bresch help up a 2-pack of EpiPen during a Congressional hearing Rising Price of…
Pfizer amps up push into obesity treatments with $4.9B deal for Metsera
Pfizer is doubling down on obesity treatments by spending $4.9 billion on the development-stage drugmaker Metsera. The COVID-19…